Biocorp

Biocorp is an expert in connectivity but develops and manufactures both connected and non-connected injectable drug delivery devices. In addition to its own connected delivery devices it also offers add-ons for existing respiratory and parenteral drug delivery systems.

Biocorp
Biocorp
Parc Technologique
Lavaur-La-Bechade
63500 Issoire
France

Phone / Contact

T: +33 (0)4 7355 7050
F: +33 (0)4 7355 0186
E: [email protected]

Connect

Biocorp develops and manufactures both connected and non-connected drug delivery devices. It is an expert in connectivity, developing its own connected delivery devices and also add-ons for existing respiratory and parenteral drug delivery systems.

Its “non connected” drug delivery devices include the Newguard passive safety system, the Biopass reconstitution system, and a range of container closures.

In the area of connectivity the company offers Datapen, a connected injection pen, and OneJet, a connected autoinjector. Easylog is an add-on to connect existing injection devices, and Inspair is an add-on to connect existing inhalers.

The company offers a large range of services including digital & physical design, device development, and product manufacturing.

Biocorp is vertically integrated and features:

A manufacturing unit dedicated to the production of its devices and also devices for pharmaceutical companies
A device R&D unit that develops innovative devices for the packaging, reconstitution and delivery of drugs
An IT R&D unit specialised in health data encryption and management, as well as mobile and web app development.

Biocorp has been in business for more than 20 years and its stock is publicly traded in on the Paris Stock Exchange.

In June 2023, Novo Nordisk (Bagsværd, Denmark), which had been collaborating with Biocorp since 2021, announced it intended to acquire Biocorp, initially by acquiring a controlling stake in the company from its main shareholder, BIO JAG, followed by a mandatory simplified tender offer on all remaining outstanding shares.

Articles by Biocorp

Interview with Arnaud Guillet & Fanny Sellier

Arnaud Guillet and Fanny Sellier talk with Guy Furness about how Biocorp has become a key player in the field of connected drug delivery, discuss the current landscape for connectivity in drug delivery and update us on its two major parenteral products – Mallya and Injay – as well as looking forward to the launch of the company’s next generation of connected drug delivery solutions.

Interview with Biocorp’s Arnaud Guillet

In this exclusive interview, Arnaud Guillet of Biocorp talks with ONdrugDelivery about connectivity in the injectables space, sharing some of the insights Biocorp has gained from its decade of experience in developing connected drug delivery devices.

Interview: Arnaud Guillet, Biocorp

In this exclusive interview with ONdrugDelivery, Arnaud Guillet discusses Mallya, Biocorp’s connected clip-on for pen injectors, including Mallya’s successful launch in multiple countries this year, the factors that have played into the device’s success, and the future for Mallya, Biocorp and connectivity in the drug delivery industry.

BIOCORP’S MALLYA – CHRONICLING A SUCCESS STORY

Arnaud Guillet and colleagues from across the industry, discuss Bicorp’s Mallya add-on device for disposable insulin pens, providing details on the main country launches and key software integrations, as well as presenting initial feedback from healthcare professionals and patients.

INJAY: SIMPLE BY CHOICE, ADAPTABLE BY DESIGN

Arnaud Guillet discusses Biocorp’s Injay solution for adding connectivity to a wide variety of PFS devices, focusing on how Injay’s designed-in simplicity and flexibility makes it easily applicable across the spectrum of PFS platforms on the market today.

MALLYA: ENLIGHTENING PAST, EXCITING PRESENT, PROMISING FUTURE

Arnaud Guillet reviews the Mallya connected device platform, from the origins of the project to the current success in diabetes and deployment in other fields, and introduces the promising next-generation Mallya.

MEASURING & MANAGING MEDICATION ADHERENCE FROM CLINICAL TRIALS TO ROUTINE CARE: INJAY MEMS AS^®

Arnaud Guillet and Bernard Vrijens discuss the issue of medication non-adherence in both clinical trials and commercialised drug products, and how Biocorp’s Injay connected prefilled syringe solution combined with Aardex’s MEMS Adherence Software provides a solution.

SENSORS ARE TOOLS – BUT HOW DO YOU MAKE THEM SMART?

Gaël Senée and Arnaud Guillet explore the benefits of Mallya – a smart sensor that turns conventional injection pens into connected devices. They also discuss the crucial role Biocorp’s connected prefilled syringe, Injay, could play in future COVID-19 vaccination programmes.

PRODUCT SHOWCASE: Injay – Connected Prefilled Syringe

Biocorp presents Injay, the first prefilled syringe with built-in connectivity, providing a cost-effective and easy-to-implement solution that improves treatment adherence, upholds quality of reporting, and provides a secure treatment protocol and traceability.

Chantal Wierckx

ADDING VALUE TO PREFILLED SYRINGES: SAFETY AND CONNECTIVITY

Chantal Wierckx and Arnaud Guillet provide an update on Newguard™, Biocorp’s integrated safety device for prefilled syringes, and explore the possible advantages connectivity can bring in the context of traceability for anti-counterfeiting, in clinical trials and in vaccination campaigns.

Eric Dessertenne

COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS

As Biocorp prepares for the market launch of its connected injector pen add-on, Mallya, Eric Dessertenne and Arnaud Guillet share insights about key steps in the company’s development. The article discusses the many partnership Biocorp has entered in to, and includes a mini-interview with Sergio Monti, Plant Manager for one such partner, V.A.R.I.

Eric Dessertenne

SUCCESSFUL CONNECTED DEVICE DEVELOPMENT REQUIRES A ROBUST VALUE PROPOSITION

Eric Dessertenn discusses the current status of connectivity in healthcare, its future, benefits both in terms of addressing adherence and big data analysis, and emphasises the need for a robust business case.

PREFILLED SYRINGES

Eric Dessertenne

A MODEL FOR TRANSFORMING BREAKTHROUGH INNOVATIONS IN SUCCESSFUL PRODUCTS

Eric Dessertenne, Philippe Lesaulnier and Arnaud Guillet outline Biocorp’s approach to device design and detail two products in the company’s portfolio, Newguard and Easylog, which are anticipated for market launch next year.

Eric Dessertenne

ERIC DESSERTENNE, BIOCORP

Eric Dessertenne talks in-depth with ONdrugDelivery Magazine about the ways connectivity is developing within the pharmaceutical industry, its likely future course and how Biocorp is positioned.

Biocorp’s OneJet^® connected autoinjector

Onejet is the first motor-driven, disposable and connected autoinjector. It's compatible with standard primary containers and is customisable allowing it to easily deliver high viscosity products. Injection data (time, doses and date) are transferred to a mobile app via Bluetooth, allowing monitoring of key treatment information.

IMPROVING PATIENTS’ LIVES THROUGH CONNECTIVITY

Eric Dessertenne and Matthieu Hamon look at the importance of increasing the connectivity of drug delivery devices to improve patient compliance in the area of chronic disease management. Biocorp aims to use innovations such as Datapen™ and EasyLog™ to help create patient-centric, interconnected care, known as 4P medicine.

PREFILLED SYRINGES

Philippe Lesaulnier

NEWGUARD – PAVING THE WAY FOR A NEW SAFETY STANDARD

Needlestick injuries remain a serious concern for pharmaceutical companies involved in injectable drugs. Biocorp has been developing NewGuard™, an integrated passive safety device to tackle this problem. Throughout the development phase, Biocorp defined key elements to ensure NewGuard™ will not require unnecessary changes to be made to the PFS manufacturing process. Philippe Lesaulnier and Eric Dessertenne explain more.

ARNAUD GUILLET, BIOCORP

Arnaud Guillet discusses Biocorp’s existing connected devices, value for pharmaceutical partners, accompanying software and data architecture and Biocorp's triple expertise in medical devices, electronics and software.

Jean Vuillecard

PRODUCT SHOWCASE: BIOCORP’S INSPAIR^™

Inspair™ is a sensing technology able to measure inhalation metrics and therefore provide an accurate insight into actual doses consumed.

PREFILLED SYRINGES

Jean Vuillecard

SAFER PREFILLED SYRINGES & FEWER PROCESS CHANGES

Jean Vuillecard, Philippe Lesaulnier and Eric Dessertenne explain how, despite great innovations, adopting new syringe safety systems has always been a trade-off between safety and the cost of implementing new processes and introduce Biocorp's Newguard™, a new passive safety system integrated on prefilled syringes without such compromises being required.

Jean Vuillecard

LEVERAGE TECH TO OVERCOME PULMONARY DELIVERY BARRIERS

Jean Vuillecard and Eric Dessertenne define the limitations of traditional strategies to train, educate and track adherence with inhaled therapeutics and show how connectivity and other add-on digital tech can support these strategies healthcare providers require.

Eric Dessertenne

THE MULTIPLE VALUES OF INTEGRATED SOLUTIONS

Arnaud Guillet and Eric Dessertenne, both of Biocorp outline the potential value of the data that can be collected from integrated devices, not only for pharma companies but also for patients and payers.

Eric Dessertenne

DEVELOPING CONNECTED DEVICES TO IMPROVE THE INTEGRATED STANDARD OF CARE

Eric Dessertenne and Edouard Poisson, Business Developer discuss mHealth, integrating medical devices with software and present their mHealth product, DataPen.

Top